Navigation Links
Romark Announces Clinical Trial Results for New Influenza Drug Presented at IDSA Meeting 2011
Date:10/21/2011

TAMPA, Fla., Oct. 21, 2011 /PRNewswire/ -- Romark Laboratories announced that results of a large Phase 2B-3 US clinical trial of its new flu drug, NT-300 (nitazoxanide), will be presented as an oral late-breaking communication at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) being held in Boston, October 20-23, 2011.  

(Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO)

The clinical trial enrolled 624 patients at 74 outpatient primary care centers throughout the United States during the 2010-2011 flu season. The trial achieved its primary endpoint showing that influenza-infected patients treated with NT-300 administered 600 mg twice daily for five days experienced statistically significant reduction in time from beginning treatment to alleviation of flu symptoms compared to influenza-infected patients receiving the placebo (P=0.008).

Approximately half of the influenza-infected patients enrolled in the US clinical trial were infected with influenza A subtype H1N1 ("swine flu") with approximately 30% being infected with influenza B and 20% with influenza A subtype H3N2.

"These data are encouraging," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark.  "We currently have only two drugs to treat influenza, both neuraminidase inhibitors, and resistance is a major concern. There is an urgent need for a new drug with a different mechanism of action for treating influenza."

Data from two other Phase 2 clinical trials, including one clinical trial in children down to 12 months of age, and laboratory studies of the drug's activity against influenza viruses will also be presented at the IDSA meeting.  In total, four different communications will be presented.  The meeting is attended by infectious disease physicians, scientists and public health personnel from the United States and around the world.  

Romark plans to init
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
5. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
6. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
7. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
8. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
9. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
10. Romark Announces Data Presented at AASLD Meeting 2010
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... und KOPENHAGEN, Dänemark, 30. Juni 2015 /PRNewswire/ ... Weltmarktführer der klinischen und kommerziellen Produktion von ... heute bekannt, dass das Unternehmen im Rahmen ... der nordamerikanischen Produktionsanlage in Bothell, ... Einweg-Anlage Bioreactor 6Pack™ komplettiert hat. Die Konfiguration ...
(Date:6/30/2015)... 30, 2015  EnteroMedics Inc. (NASDAQ: ETRM ), ... technology to treat obesity, metabolic diseases, and other gastrointestinal ... offering  of 40,229,886 units. Each unit consists of one ... warrant to purchase one share of common stock, and ... share of common stock, at a purchase price of ...
(Date:6/30/2015)... 2015  Egalet Corporation (Nasdaq: EGLT ... company focused on developing, manufacturing and marketing ... from a Category 3 human abuse liability ... oral oxycodone product candidate in late-stage clinical ... enough to require daily, around-the-clock opioid treatment ...
Breaking Medicine Technology:CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 2Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 3Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 4Egalet Announces Top-Line Results from Oral Human Abuse Liability Study of Egalet-002 5
(Date:6/30/2015)... ... ... Trenton Health Team has been certified by the New Jersey Department of Human ... serving the greater Trenton community. The ACO pilot is for a three-year period, ... structure of THT, bringing together the vast majority of Trenton’s primary and specialty care ...
(Date:6/30/2015)... , ... June 30, 2015 , ... The American Lung ... at a media event in San Diego. Speakers and clean air advocates included San ... medicine, Natalie Germuska of Kindred Hospital, and Daniel Sullivan, founder and president of Sullivan ...
(Date:6/30/2015)... Los Angeles, CA (PRWEB) , ... June 30, 2015 , ... ... research team has received a $3.1 million grant to study how sensory stimuli can ... with a special emphasis on improving care for children with autism, will compare patient ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... buying eyeglasses online , finally its here, http://www.express-glasses.com is ... shipping rates, for many location, ask about shipping with DHL Express when calling ...
(Date:6/30/2015)... ... 30, 2015 , ... Rocky Mountain Oils, a leading non-MLM supplier of ... a new CEO, Mr. Darold Francis. The changes will help enhance the company’s focus ... customers have come to know and respect for over eight years. , “I am ...
Breaking Medicine News(10 mins):Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 2Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 3Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 2Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 3Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:Rocky Mountain Oils Adds New CEO, Announces Relocation of Operations to Orem, Utah 2
... the #1 co-ed,fitness club chain in the world, has ... has clubs operating in 46 states, Canada and Australia,serving ... other well-known fitness chains have recently scaled back their,expansion ... grow at,an impressive rate. In fact, in the past ...
... the eye region is also useful when trying to spot fatigue ... or less tired? Focus on the area around your eyes, a ... your age and level of fatigue. , When asked to ... looked at the eye region almost half the time, researchers ...
... profound impact on this country,s psyche. Eight years after ... events affected us. A number of studies have shown ... the terrorist attacks experienced heightened levels of stress and ... Research has also indicated that elevated levels of stress ...
... PARK, N.J. and NEW YORK, Feb. 2 HLTH Corporation ... subsidiary, WebMD Health Corp. (Nasdaq: WBMD ), today ... the three months ended December 31, 2008 at approximately 4:00 ... will host a conference call at 4:45 pm (ET) on ...
... SCOLR Pharma, Inc. (NYSE Alternext US: DDD) today announced ... Ph.D., M.B.A., to serve as president and chief executive officer. ... SCOLR Pharma board of directors since August 2007.Michael N. Taglich, ... very pleased that Dr. Morra has agreed to become SCOLR ...
... (TFAH) strongly supports President Obama,s call for a "complete ... outbreak of Salmonella tied to peanut butter ... Salmonella outbreaks in 2008 highlight the need ... released a comprehensive report, Fixing Food Safety: Protecting ...
Cached Medicine News:Health News:Anytime Fitness Opens 1,000th Club 2Health News:Anytime Fitness Opens 1,000th Club 3Health News:When Gauging Age, the Eyes Have It 2Health News:Driving under the influence (of stress): Regional effects of 9/11 attacks on driving 2Health News:HLTH and WebMD Announce Fourth Quarter Earnings Release Date and Conference Call 2Health News:SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO 2Health News:SCOLR Pharma, Inc. Announces Appointment of Bruce S. Morra, Ph.D., as President & CEO 3Health News:Trust for America's Health Applauds President Obama's Call for a Complete Review of the U.S. Food Safety System 2Health News:Trust for America's Health Applauds President Obama's Call for a Complete Review of the U.S. Food Safety System 3
... Inc. (DAI) Myeloperoxidase (MPO) Enzyme-Linked Immunosorbent Assay ... semi-quantitative determination of IgG, A, M antibodies ... is used to detect antibodies in ... the assay are to be used as ...
... ELISA is a solid phase two-site ... the direct sandwich technique in which ... separate antigenic determinants on the insulin ... sample react with peroxidase-conjugated anti-insulin antibodies ...
Anti-RSV IgM Assay (ELISA)....
Anti-RSV IgG Assay (ELISA)....
Medicine Products: